Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
TATIN trial: what clinicians have said so far
ctDNA Guided Treatment of Early Resistance to Targeted Treatment
- NCT04148066 ↗
- Completed
- The Netherlands Cancer Institute
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on TATIN yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TATIN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 YouTube videos, typically up to 9 once built | |
| 1 post on X, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Track and Treat in NSCLC (TATIN) - ctDNA Guided Treatment of Early Resistance to Targeted Treatment in Patients With EGFR Positive NSCLC
- Phase
- Phase not applicable
- Status
- Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- ctDNA blood sample
- Arms
- Osimertinib and Crizotinib · Other
- Enrollment
- 104
- Primary outcomes
- percentage of patients in which a drug resistant clone can be detected with ctDNA
- Sponsor
- The Netherlands Cancer Institute with Roche Pharma AG
- Start
- Jul 17, 2019
- Primary completion
- Dec 17, 2021
- Results posted
- No
- Registry record
- NCT04148066 · updated Oct 10, 2023